BCL2 and gastrointestinal stromal tumor: Similarly, Steinert et al. [24] defined BCL2 positivity as any detectable cytoplasmic staining and demonstrated that BCL2 positivity was associated with longer DFS in patients with advanced GIST treated with imatinib.